Previous 10 | Next 10 |
Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced confidentially marketed public offering with healthcare-focused U.S. institutional investors for the purchase of 5,004,545 shares of the Company’s common stock (or common stock equivalents in li...
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today that it intends to file its quarterly report on Form 10-Q for the three months ended September 30, 2022 with the U.S. Securit...
Athersys ( NASDAQ: ATHX ) stock sank 44% before the bell on Wednesday after the firm priced its public offering of ~5M shares and warrants to buy ~10M shares at a combined price of $1.10/share and accompanying warrant for total proceeds of ~$5.5M. The warrants will hav...
Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced the pricing of its previously announced "best efforts" public offering of 5,004,545 shares of common stock (or common stock equivalents) and warrants to purchase 10,009,090 shares of ...
Athersys ( NASDAQ: ATHX ) stock tumbled 40.3% postmarket on Monday after the firm announced a proposed public offering of shares and warrants. There can be no assurance as to whether or when the offering may be completed. Athersys ( ATHX ) intends to use n...
Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock, subject to market and other condition...
Summary Due to an extended downtrend in Athersys stock price due largely to a declining cash position, Athersys currently trades at a market cap near $24 million. The current valuation is miniscule when compared to valuations of other stem cell companies, especially when consideri...
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today their participation in two October conferences, the 2022 Cell & Gene Meeting on the Mesa on October 11-13, 2022 and the 14 ...
Athersys, Inc. (NASDAQ: ATHX) , a regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today it will host a business update conference call on October 6, 2022 at 4:00 pm Eastern Time. Dan Camardo, Chief Executive Offi...
3 Penny Stocks to Add to Your Watchlist This Week Are penny stocks worth it right now? That’s a tough question to answer, as there are pros and cons to consider. On the one hand, penny stocks are often seen as a high-risk investment, so there’s definitely potential for...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...